Custom Protein Generation

Drug Substance Manufacture

Drug Product Fill & Finish

Development

Testing

Discovery

Antibody Drug Conjugates

Technologies & Platforms

Latest News

2018/12/13
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development

2018/12/12
WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity

2018/12/11
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

2018/12/10
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics

2018/12/06
WuXi Biologics Wins SCRIP Award for “Best Company in an Emerging Market”

2018/12/05
WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

2018/11/29
WuXi Biologics Selected as Forbes Asia’s Best Under A Billion 2018

2018/11/28
WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies

2018/11/22
WuXi Biologics Commenced Construction of 1.6 million sq. ft. Biologics Innovation Center in Shanghai

2018/11/07
WuXi Biologics’ Chief Executive Officer Dr. Chris Chen to Serve on Board of Directors at ISPE and Delivered Keynote Speech at 2018 Annual Meeting

2018/10/31
WuXi Biologics Commenced Construction of 48,000L Biologics Commercial Manufacturing Center in Shijiazhuang

2018/10/29
WuXi Biologics Congratulates Tychan on Completing Human Safety Studies for the First-in-Class Zika Virus Antibody in Record Speed

2018/10/23
CANbridge Pharmaceutical and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics

2018/09/26
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs

2018/09/25
WuXi Biologics Appoints Harvard Professor David R. Liu to Scientific Advisory Board

2018/09/18
WuXi Biologics’ Chief Quality Officer Received Foreign Post Service Award from FDA

2018/09/11
WuXi Biologics and Inhibrx Enter an Exclusive Partnership for GMP Manufacturing

2018/08/30
WuXi Biologics Selected into the Hang Seng HK 35 Index

2018/08/20
WuXi Biologics Reports Robust 2018 Interim Results

2018/07/31
WuXi Biologics Commenced Process Validation in MFG2

2018/07/25
WuXi Biologics Announced Successful Completion of the First cGMP Run in MFG3

2018/07/09
WuXi Biologics and Immune Pharmaceuticals Announce Late-Phase Development and Manufacturing Partnership for a First-In-Class Monoclonal Antibody

2018/06/25
WuXi Biologics and Harbour BioMed Announce Strategic Development and Manufacturing Partnership

2018/06/20
WuXi Biologics Initiated Construction of a State-of-the-Art Integrated ADC Solution Center

2018/06/11
WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United States

2018/05/30
WuXi Biologics and Tsinghua University Innovation Center for Immune Therapy Sign MOU and Announce Strategic Partnership

2018/05/22
WuXi Biologics to Invest S$80 Million to Establish a Biologics Manufacturing Facility in Singapore

2018/05/21
WuXi Biologics and Bioasis Announce Initial Strategic Collaboration for the Development and Manufacturing of Bioasis’ Lead Investigational Candidate to Treat Brain Cancer

2018/05/16
WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang

2018/05/14
WuXi Biologics Congratulates Aravive Biologics on Achieving Proof-of-Mechanism for Novel Biologic AVB-S6-500 within 20 Months from Cell Line Development

2018/04/30
WuXi Biologics to Invest €325 Million to Build Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

2018/04/17
WuXi Biologics Wins CMO Leadership Award from Life Science Leader Magazine

2018/03/21
WuXi Biologics to Install Industry’s Largest Single-Use Bioreactor from ABEC at its New Commercial Manufacturing Facility

2018/03/19
WuXi Biologics Reports Remarkable 2017 Annual Results: Revenue up 63.7% to a Record High of RMB1,618.8 Million

2018/03/09
WuXi Biologics and Adagene Announce Strategic Development and Manufacturing Partnership

2018/03/07
WuXi Biologics Congratulates TaiMed on FDA Approval for Trogarzo

2018/03/06
WuXi Biologics Receives Asia’s CMO of 2017 from BioPharma Industry Awards

2018/03/05
WuXi Biologics Announces Positive Profit Alert

2018/02/27
WuXi Biologics Congratulates MabSpace on FDA Clearance of IND for MSB2311

2018/02/13
WuXi Biologics Receives Two Bioprocessing Awards from IMAPAC

2018/02/09
WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development

2018/01/31
WuXi Biologics Congratulates BioAtla on FDA Clearance of IND Application for CAB-AXL-ADC

2018/01/30
WuXi Biologics and Aravive Biologics to Form Strategic Manufacturing Collaboration Following Successful IND Filing for AVB-S6-500

2018/01/24
WuXi Biologics Announces Formation of Scientific Advisory Board

2018/01/15
WuXi Biologics Appoints Dr. Chiang Syin, a Former FDA Officer as Chief Quality Officer

2018/01/09
WuXi Biologics Receives Best IPO Award and Best Investor Relations Award 2017

 

See below for other press releases by year.

2017       2016       2015       2014         2013         2012


 

Upcoming Events

J.P. Morgan Healthcare Conference

Biotech Showcase Conference

WuXi AppTec Global Forum

January 7-10, 2019 | San Francisco, CA

Meet us at the event

 

Peptalk

January 14-18, 2019 | San Diego, CA

Meet us at the event

 

BACK